期刊文献+

过氧化物酶体增殖物激活受体δ下调载脂蛋白F在肝细胞中的表达

Peroxisome Proliferator Activated Receptor Delta Agonist Downregulates the Expression of Apolipoprotein F in Liver Cells
下载PDF
导出
摘要 目的探讨过氧化物酶体增殖物激活受体δ(PPARδ)对载脂蛋白F(ApoF)基因转录的调控作用及机制。方法使用不同浓度PPARδ激动剂GW0742干预HepG2细胞株,Realtime PCR检测ApoF的mRNA水平,Western-blot检测ApoF的蛋白水平;构建ApoF启动子双荧光素酶报告基因重组载体,与PPAR激动剂共转染肝细胞;双荧光素酶报告基因系统检测PPARδ激动剂对启动子活性的影响。结果经不同浓度PPARδ激动剂GW0742处理后,10μmol/L以上浓度的ApoF mRNA及蛋白水平显著低于未处理组;PPARδ激动剂可以显著降低ApoF的启动子活性。结论PPARδ可以通过调控ApoF启动子的活性下调其mRNA及蛋白的表达水平。 Objective Apolipoprotein F regulates the activity of cholesterol ester transporters.Previous studies have found that its upstream promoter region is regulated by ETS and CEP transcription,and further studies on the role and possible mechanism of PPAR in apolipoprotein F are proposed.Methods Using different concentrations of PPARδagonists(GW0742)to intervene the cell lines to detect apolipoprotein F mRNA levels by Realtime-PCR,in addition,the upstream promoter of double fluorescent reporter enzyme apolipoprotein was constructed by gene cloning and co-transfected into hepatocytes with PPAR agonists.The effect of PPARδagonists on promoter activity was detected by double fluorescent reporter enzyme gene.Results The ApoF mRNA level of PPARδgroup with concentration above 10μmol was significantly lower than that of untreated group after treated with different concentrations of agonists.PPARδagonists can significantly reduce the activity of ApoF promoter.Conclusion PPARδcan down-regulated the expression level of Apo-F protein and mRNA by regulating the activity of ApoF promoter.
作者 沈雪彬 徐尚华 林小端 SHEN Xuebin;XU Shanghua;LIN Xiaoduan(Department of Cardiology, The Affiliated Nanping First Hospital of Fujian Medical University, Nanping 353000, China)
出处 《福建医科大学学报》 2020年第6期378-381,共4页 Journal of Fujian Medical University
基金 福建省卫生计生委青年科研课题(2015-1-108)。
关键词 过氧化物酶体增殖物激活受体 载脂蛋白类 动脉粥样硬化 peroxisome proliferator-activated receptors apolipoproteins atherosclerosis
  • 相关文献

参考文献2

二级参考文献18

  • 1Hung MJ,Cherng WJ,Cheng CW,et al.Comparison of serum levels of inflammatory markers in patients with coronary vasospasm without significant fixed coronary artery disease versus patients with stable angina pectoris and acute coronary syndromes with significant fixed coronary artery disease[J].Am J Cardiol,2006,97(10):1429-1434.
  • 2Inoue S,Egashira K,Ni W,et al.Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice[J].Circulation,2002,106(21):2700-2706.
  • 3Griendling KK,FitzGerald GA.Oxidative stress and cardiovascular injury.Part I:basic mechanisms and in vivo monitoring of ROS[J].Circulation,2003,108(16):1912-1916.
  • 4Park JG,Oh GT.The role of peroxidases in the pathogenesis of atherosclerosis[J].BMB Rep,2011,44(8):497-505.
  • 5Hulsmans M,Holvoet P.The vicious circle between oxidative stress and inflammation in atherosclerosis[J].J Cell Mol Med,2010,14(1-2):70-78.
  • 6Tribouilloy CM,Peltier M,Iannetta Peltier MC,et al.Plasma homocysteine and severity of thoracic aortic atherosclerosis[J].Chest,2000,118(6):1685-1689.
  • 7Woo CW,Siow YL,O K.Homocysteine induces monocyte chemoattractant protein-1 expression in hepatocytes mediated via activator protein-1 activation[J].J Biol Chem,2008,283(3):1282-1292.
  • 8Wang N.PPAR-δ in vascular pathophysiology[J].PPAR Res,2008,2008:164163.
  • 9Bishop-Bailey D,Bystrom J.Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation[J].Pharmacol Ther,2009,124(2):141-150.
  • 10Lemos JA,Morrow DA,Sabatine MS,et al.Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes[J].Circulation,2003,107(5):690-695.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部